Skip to main content
Thorax logoLink to Thorax
. 1981 Oct;36(10):741–744. doi: 10.1136/thx.36.10.741

Intravenous salbutamol and aminophylline in asthma: a search for synergy.

P D Handslip, A M Dart, B H Davies
PMCID: PMC471747  PMID: 7330791

Abstract

The bronchodilation produced by increasing intravenous doses of aminophylline, salbutamol, and a combination of aminophylline and salbutamol given in random order was determined in 10 stable asthmatics on three consecutive days. On a fourth day, response to placebo injections was determined. Forced expiratory volume in one second (FEV1) was measured at two-minute intervals after each dose until FEV1 returned to a new baseline. At no dosage level was there synergy between the two agents in terms of either mean percentage increase in FEV1 or the integrated response. The failure to demonstrate synergy has implications both with respect to the clinical use and the underlying mechanism of action of these drugs.

Full text

PDF
741

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BUTCHER R. W., SUTHERLAND E. W. Adenosine 3',5'-phosphate in biological materials. I. Purification and properties of cyclic 3',5'-nucleotide phosphodiesterase and use of this enzyme to characterize adenosine 3',5'-phosphate in human urine. J Biol Chem. 1962 Apr;237:1244–1250. [PubMed] [Google Scholar]
  2. Boksay I., Bollmann V. The effect of 3,7-dimethyl-1-(5-oxo-hexyl)-xanthin on the -adrenergic receptors and on the activity of isoprenaline. Arch Int Pharmacodyn Ther. 1971 Nov;194(1):174–180. [PubMed] [Google Scholar]
  3. Campbell I. A., Middleton W. G., McHardy G. J., Shotter M. V., McKenzie R., Kay A. B. Interaction between isoprenaline and aminophylline in asthma. Thorax. 1977 Aug;32(4):424–428. doi: 10.1136/thx.32.4.424. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Kaliner M. A., Orange R. P., Koopman W. J., Austen K. F., Laraia P. J. Cyclic adenosine 3',5'-monophosphate in human lung. Biochim Biophys Acta. 1971 Oct;252(1):160–164. doi: 10.1016/0304-4165(71)90104-8. [DOI] [PubMed] [Google Scholar]
  5. Kunos G. Adrenoceptors. Annu Rev Pharmacol Toxicol. 1978;18:291–311. doi: 10.1146/annurev.pa.18.040178.001451. [DOI] [PubMed] [Google Scholar]
  6. Lichtenstein L. M., Margolis S. Histamine release in vitro: inhibition by catecholamines and methylxanthines. Science. 1968 Aug 30;161(3844):902–903. doi: 10.1126/science.161.3844.902. [DOI] [PubMed] [Google Scholar]
  7. Reuter H., Scholz H. The regulation of the calcium conductance of cardiac muscle by adrenaline. J Physiol. 1977 Jan;264(1):49–62. doi: 10.1113/jphysiol.1977.sp011657. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Terasaki W. L., Brooker G. Cardiac adenosine 3':5'-monophosphate. Free and bound forms in the isolated rat atrium. J Biol Chem. 1977 Feb 10;252(3):1041–1050. [PubMed] [Google Scholar]
  9. VELDSTRA H. Synergism and potentiation with special reference to the combination of structural analogues. Pharmacol Rev. 1956 Sep;8(3):339–387. [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES